Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Pediatr Transplant ; 24(1): e13594, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31680369

RESUMO

Both acute GVHD and chronic GVHD remain the leading cause of morbidity and death after allogeneic HSCT. We conducted a retrospective analysis comparing two GVHD-prophylaxis regimens: 35 patients received "Regimen 1" (horse ATG, tacrolimus, and methotrexate) and 46 "Regimen 2" (rabbit ATG, rituximab, and peritransplant bortezomib). All 81 patients with a median age of 9 (0.6-23) years with ALL (n = 31) or AML (n = 50) in complete remission received TCRαß/CD19-depleted transplants between May 2012 and October 2016, from 40 HLA-matched unrelated and 41 haploidentical donors. After a median follow-up of 3.9 years, the CI of acute GVHD II-IV was 15% (95% CI: 7-30) in the "Regimen 2" group and 34% (95% CI: -54) in the "Regimen 1" group, P = .05. "Regimen 2" was also more effective in the prevention of chronic GVHD; the CI at 1 year after HSCT was 7% (95% CI: 2-19) vs 31% (95% CI: 19-51), P = .005. The CI of relapse at 3 years adjusted for the GVHD-prophylaxis regimen groups 31% (95% CI: 19-51) for the "Regimen 1" vs 21% (95% CI: 11-37) for the "Regimen 2", P = .3. The retrospective observation suggests that the use of the rATG, rituximab, and bortezomib was associated with significantly lower rate of GVHD without the loss of anti-leukemic activity.


Assuntos
Soro Antilinfocitário/uso terapêutico , Bortezomib/uso terapêutico , Doença Enxerto-Hospedeiro/prevenção & controle , Transplante de Células-Tronco Hematopoéticas , Imunossupressores/uso terapêutico , Leucemia/terapia , Rituximab/uso terapêutico , Adolescente , Antígenos CD19 , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Seguimentos , Transplante de Células-Tronco Hematopoéticas/métodos , Humanos , Lactente , Leucemia/imunologia , Masculino , Receptores de Antígenos de Linfócitos T alfa-beta , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
2.
Cell Cycle ; 11(22): 4222-41, 2012 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-23095639

RESUMO

There is a relationship between various cellular stress factors and aging. In earlier studies, we demonstrated that overexpression of the D-GADD45 gene increases the life span of Drosophila melanogaster. In this study, we investigate the relationship between D-GADD45 activity and resistance to oxidative, genotoxic and thermal stresses as well as starvation. In most cases, flies with constitutive and conditional D-GADD45 overexpression in the nervous system were more stress-resistant than ones without overexpression. At the same time, most of the studied stress factors increased D-GADD45 expression in the wild-type strain. The lifespan-extending effect of D-GADD45 overexpression was also retained after exposure to chronic and acute gamma-irradiation, with doses of 40 сGy and 30 Gy, respectively. However, knocking out D-GADD45 resulted in a significant reduction in lifespan, lack of radiation hormesis and radioadaptive response. A dramatic decrease in the spontaneous level of D-GADD45 expression was observed in the nervous system as age progressed, which may be one of the causes of the age-related deterioration of organismal stress resistance. Thus, D-GADD45 expression is activated by most of the studied stress factors, and D-GADD45 overexpression resulted in an increase of stress resistance.


Assuntos
Proteínas de Drosophila/metabolismo , Raios gama , Herbicidas/toxicidade , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Animais , Proteínas de Drosophila/genética , Drosophila melanogaster/metabolismo , Resistência a Medicamentos , Feminino , Genótipo , Hormese , Peptídeos e Proteínas de Sinalização Intracelular/genética , Longevidade , Masculino , Mutação , Sistema Nervoso/metabolismo , Paraquat/toxicidade , Inanição , Temperatura , Proteínas GADD45
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa